Novartis Pitching New Product: A Fund For Tropical Disease Research
Executive Summary
Novartis executive Paul Herrling has been on a whirlwind promotional tour the past few weeks. He's met with government leaders in China, Germany and the Netherlands, and academicians at Yale University, Columbia University and the New York Academy of Sciences. His goal: convincing them to support a new way to fund research on medicines for tuberculosis, dengue fever and other neglected tropical diseases
You may also be interested in...
R&D For Diseases Of Developing Countries Could Be Driven By Pooled Funds
WHO committee backs use of pooled funds to finance R&D, nixes priority review vouchers and finds no need for data exclusivity. Novartis’ Paul Herrling, a committee member, notes that governments would be responsible for R&D costs.
FDA Awards First-Ever Priority Review Voucher To Novartis For Coartem Approval
Coartem clears FDA for acute, uncomplicated malaria; agency finds it effective in regions where people are resistant to chloroquine.
GSK Wades Into The Pooled Approach To Tropical Disease Research
GlaxoSmithKline CEO Andrew Witty's proposal for companies to pool their patents to develop medicines for neglected tropical diseases is a somewhat unusual call for collaboration in the pharmaceutical industry, but not entirely without precedent